Friedman Joseph H
Butler Hospital, Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI.
Clin Neuropharmacol. 2017 Jul/Aug;40(4):157-159. doi: 10.1097/WNF.0000000000000219.
Pimavanserin, a 5-HT2A inverse agonist, was commercially released in the United States in April 2016 for the treatment of Parkinson disease psychosis. No "naturalistic" treatment results have yet been published. Charts from the movement disorders clinic were reviewed for all patients who received this drug as treatment for psychosis associated with primary parkinsonism due to α-synucleinopathies. Data of 10 patients with idiopathic Parkinson disease, including 1 with a long history of schizophrenia, 4 with dementia with Lewy bodies, and 1 with multiple-system atrophy, were reviewed. There were no adverse events reported. Ten patients improved and continue on the drug, whereas 5 stopped because of lack of benefit.
匹莫范色林是一种5-羟色胺2A反向激动剂，于2016年4月在美国上市，用于治疗帕金森病精神病。目前尚未发表“自然主义”治疗结果。对运动障碍诊所的病历进行了回顾，这些病历涉及所有接受该药物治疗与α-突触核蛋白病相关的原发性帕金森病精神病的患者。回顾了10例特发性帕金森病患者的数据，其中包括1例有长期精神分裂症病史的患者、4例路易体痴呆患者和1例多系统萎缩患者。未报告不良事件。10例患者病情改善并继续使用该药物，而5例患者因无疗效而停药。
